JP7181325B2 - がんを処置するための方法 - Google Patents

がんを処置するための方法 Download PDF

Info

Publication number
JP7181325B2
JP7181325B2 JP2021031341A JP2021031341A JP7181325B2 JP 7181325 B2 JP7181325 B2 JP 7181325B2 JP 2021031341 A JP2021031341 A JP 2021031341A JP 2021031341 A JP2021031341 A JP 2021031341A JP 7181325 B2 JP7181325 B2 JP 7181325B2
Authority
JP
Japan
Prior art keywords
compound
cancer
pharmaceutically acceptable
acceptable salt
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021031341A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021138693A (ja
JP2021138693A5 (https=
Inventor
スー ボアーナ カリン
ユックファイ ウォン ジム
Original Assignee
アレイ バイオファーマ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレイ バイオファーマ インコーポレイテッド filed Critical アレイ バイオファーマ インコーポレイテッド
Publication of JP2021138693A publication Critical patent/JP2021138693A/ja
Publication of JP2021138693A5 publication Critical patent/JP2021138693A5/ja
Priority to JP2022183924A priority Critical patent/JP2023009250A/ja
Application granted granted Critical
Publication of JP7181325B2 publication Critical patent/JP7181325B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021031341A 2020-03-03 2021-03-01 がんを処置するための方法 Active JP7181325B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022183924A JP2023009250A (ja) 2020-03-03 2022-11-17 がんを処置するための方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062984458P 2020-03-03 2020-03-03
US62/984458 2020-03-03
US202163133501P 2021-01-04 2021-01-04
US63/133501 2021-01-04

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022183924A Division JP2023009250A (ja) 2020-03-03 2022-11-17 がんを処置するための方法

Publications (3)

Publication Number Publication Date
JP2021138693A JP2021138693A (ja) 2021-09-16
JP2021138693A5 JP2021138693A5 (https=) 2022-03-09
JP7181325B2 true JP7181325B2 (ja) 2022-11-30

Family

ID=74860342

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021031341A Active JP7181325B2 (ja) 2020-03-03 2021-03-01 がんを処置するための方法
JP2022183924A Pending JP2023009250A (ja) 2020-03-03 2022-11-17 がんを処置するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022183924A Pending JP2023009250A (ja) 2020-03-03 2022-11-17 がんを処置するための方法

Country Status (12)

Country Link
US (1) US20230117328A1 (https=)
EP (1) EP4114397A1 (https=)
JP (2) JP7181325B2 (https=)
KR (1) KR20220148867A (https=)
CN (1) CN115529816A (https=)
AU (1) AU2021231435A1 (https=)
BR (1) BR112022017267A2 (https=)
CA (1) CA3174064A1 (https=)
IL (1) IL296060A (https=)
MX (1) MX2022010955A (https=)
TW (2) TWI814504B (https=)
WO (1) WO2021176330A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023002360A1 (en) * 2021-07-22 2023-01-26 Pfizer Inc. Solid forms and formulations of an inhibitor of tam and c-met kinases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
US10329570B2 (en) 2014-07-31 2019-06-25 Academia Sinica Antagonistic PD-1 aptamer and its applications in cancer therapy related applications
ES2831416T3 (es) * 2014-07-31 2021-06-08 Novartis Ag Terapia de combinación de un inhibidor de MET y un inhibidor de EGFR
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
UY38349A (es) * 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cancer Immunol. Res.，2019年，Vol.7(10)，pp.1672-1686

Also Published As

Publication number Publication date
CN115529816A (zh) 2022-12-27
US20230117328A1 (en) 2023-04-20
TWI814504B (zh) 2023-09-01
JP2021138693A (ja) 2021-09-16
EP4114397A1 (en) 2023-01-11
TW202317125A (zh) 2023-05-01
IL296060A (en) 2022-10-01
AU2021231435A1 (en) 2022-09-22
TWI775333B (zh) 2022-08-21
BR112022017267A2 (pt) 2022-12-13
TW202146025A (zh) 2021-12-16
JP2023009250A (ja) 2023-01-19
KR20220148867A (ko) 2022-11-07
CA3174064A1 (en) 2021-09-10
WO2021176330A1 (en) 2021-09-10
MX2022010955A (es) 2022-10-07

Similar Documents

Publication Publication Date Title
BR112019021880A2 (pt) Terapia de combinação com conjugado anticorpo anti-axl-droga
AU2017275650B2 (en) Pharmaceutical combinations
CN114945369A (zh) 图卡替尼与抗her2抗体-药物缀合物联合治疗her2阳性乳腺癌的方法
CN114302745A (zh) 包含抗cd19抗体药物缀合物以及pi3k抑制剂或第二剂的组合疗法
JP7181325B2 (ja) がんを処置するための方法
JP2021511344A (ja) 癌を治療する組成物および方法
KR20230110254A (ko) Sting 작용제, 관문 저해제, 및 방사선의 투여
JP2026501925A (ja) Ｈｅｒ２阻害剤の固体分散剤の投与スケジュール
HK40079302A (en) Methods to treat cancer using (r)-n-(3-fluoro-4-((3-((1-hydroxypropan-2-yl)amino)-1h-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
CA3087844A1 (en) Methods and combination therapy to treat cancer
TW202308641A (zh) 用於治療癌症之方法及包含cdk抑制劑之給藥方案
US20260034134A1 (en) Treatment of cancer with metastases in the central nervous system
RU2777519C2 (ru) Применение ингибитора parp в лечении резистентного к химиотерапии рака яичников или рака молочной железы
WO2024263960A2 (en) Compositions comprising antineoplastons and methods of treating lung cancer
WO2024263801A2 (en) Compositions comprising antineoplastons and methods of treating ovarian cancer
EP4731793A2 (en) Compositions comprising antineoplastons and methods of treating pancreatic cancer
WO2024263643A1 (en) Compositions comprising antineoplastons and methods of treating breast cancer
EP4731199A2 (en) Compositions comprising antineoplastons and methods of treating colorectal cancer
WO2024263798A1 (en) Compositions comprising antineoplastons and methods of treating prostate cancer
US20190211102A1 (en) Methods and combination therapy to treat cancer
CN116490244A (zh) Sting激动剂、检查点抑制剂和辐射的施用
HK40078614A (en) Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
HK40028739A (en) Methods and combination therapy to treat cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220301

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220301

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221006

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221026

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221117

R150 Certificate of patent or registration of utility model

Ref document number: 7181325

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150